Heppt MV - Search Results

1

Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set.

Heppt MV, Steeb T, Schmitz L, Garbe C, French LE, Leiter U, Berking C. Heppt MV, et al. Trials. 2019 Oct 11;20(1):589. doi: 10.1186/s13063-019-3696-6. Trials. 2019. PMID: 31604473 Free PMC article.

2

Combination therapy of melanoma using kinase inhibitors.

Heppt MV, Tietze JK, Graf SA, Berking C. Heppt MV, et al. Curr Opin Oncol. 2015 Mar;27(2):134-40. doi: 10.1097/CCO.0000000000000160. Curr Opin Oncol. 2015. PMID: 25602684 Review.

3

Clinicopathologic features of primary cutaneous melanoma: a single centre analysis of a Swiss regional population.

Heppt MV, Reinholz M, Tietze JK, Kerl K, French LE, Berking C, Kamarashev J. Heppt MV, et al. Eur J Dermatol. 2015 Apr;25(2):127-32. doi: 10.1684/ejd.2014.2500. Eur J Dermatol. 2015. PMID: 25787976

4

Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor.

Heppt MV, Tietze JK, Reinholz M, Rahimi F, Jung A, Kirchner T, Ruzicka T, Flaig MJ, Berking C. Heppt MV, et al. Discov Med. 2015 Oct;20(110):231-7. Discov Med. 2015. PMID: 26562476 Free article.

5

Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.

Heppt MV, Eigentler TK, Kähler KC, Herbst RA, Göppner D, Gambichler T, Ulrich J, Dippel E, Loquai C, Schell B, Schilling B, Schäd SG, Schultz ES, Matheis F, Tietze JK, Berking C. Heppt MV, et al. Cancer Immunol Immunother. 2016 Aug;65(8):951-9. doi: 10.1007/s00262-016-1856-z. Epub 2016 Jun 13. Cancer Immunol Immunother. 2016. PMID: 27294607

6

A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma.

Matheis F, Heppt MV, Graf SA, Düwell P, Kammerbauer C, Aigner A, Besch R, Berking C. Matheis F, et al. Among authors: heppt mv. J Invest Dermatol. 2016 Dec;136(12):2475-2484. doi: 10.1016/j.jid.2016.07.026. Epub 2016 Aug 3. J Invest Dermatol. 2016. PMID: 27498344 Free article.

7

[What is new in basal cell carcinoma?].

Heppt M, von Braunmühl T, Berking C. Heppt M, et al. Hautarzt. 2016 Nov;67(11):876-883. doi: 10.1007/s00105-016-3880-5. Hautarzt. 2016. PMID: 27654826 Review. German.

8

The Systemic Management of Advanced Melanoma in 2016.

Heppt MV, Dietrich C, Graf SA, Ruzicka T, Tietze JK, Berking C. Heppt MV, et al. Oncol Res Treat. 2016;39(10):635-642. doi: 10.1159/000448904. Epub 2016 Sep 14. Oncol Res Treat. 2016. PMID: 27710977 Review.

9

Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.

Hornig E, Heppt MV, Graf SA, Ruzicka T, Berking C. Hornig E, et al. Among authors: heppt mv. Exp Dermatol. 2016 Nov;25(11):831-838. doi: 10.1111/exd.13089. Exp Dermatol. 2016. PMID: 27792246 Review.

10

Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.

Tietze JK, Angelova D, Heppt MV, Ruzicka T, Berking C. Tietze JK, et al. Among authors: heppt mv. Exp Dermatol. 2017 Jul;26(7):622-629. doi: 10.1111/exd.13263. Epub 2017 Feb 19. Exp Dermatol. 2017. PMID: 27892653

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page